sermorelin sarcopenia: Frequently asked questions

GH has insulin-antagonistic effects. It reduces peripheral glucose uptake temporarily while mobilizing fatty acids for energy. Morning fasting glucose increases of 5–10mg/dL are common during the first 4–8 weeks of sermorelin therapy and typically normalize as insulin sensitivity adapts. If fasting glucose rises above 110mg/dL persistently, reduce sermorelin dose by 25% (e.g., from 500mcg to 375mcg) and reassess after four weeks. Combining sermorelin with metformin 500mg nightly can mitigate glucose elevation without compromising IGF-1 response. Metformin improves insulin sensitivity without interfering with GH-IGF-1 signaling.

Elevated IGF-1 without corresponding lean mass gain suggests anabolic resistance at the muscle level rather than a pituitary issue. Sarcopenic muscle often exhibits blunted mTOR activation even when IGF-1 is adequate, a phenomenon linked to chronic low-grade inflammation and insufficient dietary protein intake. The leucine threshold for mTOR activation in older adults is 2.5–3g per meal. Achieving this with 30–40g high-quality protein per meal is necessary for IGF-1 to translate into muscle protein synthesis. Resistance training 3–4 times weekly amplifies sermorelin's anabolic effects by sensitizing muscle to IGF-1 signaling.

Verify peptide quality through third-party HPLC analysis. If the amino acid sequence is incorrect or the peptide has undergone oxidative degradation during storage, GHRH receptor binding will fail. Sermorelin must be stored at −20°C before reconstitution and between 2–8°C after mixing with bacteriostatic water. Temperature excursions above 8°C denature the peptide structure irreversibly. If storage was correct and IGF-1 remains unchanged, assess cortisol and thyroid function. Chronic hypercortisolemia and untreated hypothyroidism both suppress pituitary GH responsiveness to GHRH stimulation.

The peptide has degraded beyond usability. Sermorelin's 29-amino-acid sequence undergoes rapid oxidation and deamidation at temperatures above 8°C, with particularly vulnerable sites at methionine-27 and tyrosine-1. A 72-hour room-temperature exposure causes >60% loss of bioactivity even if the solution remains visually clear. Reconstituted sermorelin must be refrigerated at 2–8°C continuously and used within 28 days. If a vial was left out overnight, assume it's inactive and replace it rather than risking weeks of wasted protocol time with a degraded compound.

Discard it immediately. Cloudiness indicates peptide aggregation or bacterial contamination, both of which render the compound inactive and potentially unsafe for injection. Sermorelin acetate should produce a clear, colorless solution when reconstituted with bacteriostatic water at the correct pH. Cloudiness typically results from alkaline pH (>7.0), non-sterile water, or improper mixing technique (shaking instead of gentle swirling). Aggregated peptides cannot bind GHRH receptors and produce no biological effect. Never use a cloudy solution in a research protocol. The data will be meaningless.

The protocol will likely show attenuated or null results despite correct dosing. GH receptor expression in skeletal muscle follows a circadian rhythm, peaking during nocturnal hours. Administering sermorelin at circadian trough means lower receptor occupancy and reduced downstream IGF-1 signaling even if GH secretion is elevated. A study in aged rodents found that midday dosing produced only 42% of the lean mass gains seen with evening dosing at identical dose levels. If timing constraints prevent evening administration, document this as a protocol deviation and expect reduced effect sizes in outcome measures.

This indicates downstream resistance in the GH/IGF-1 signaling pathway. A common feature of advanced sarcopenia that sermorelin alone may not overcome. GH receptor density in liver and muscle tissue declines with age, and even elevated GH levels may fail to produce proportional IGF-1 increases if receptor expression is severely impaired. Some protocols combine sermorelin with mTOR activators or leucine supplementation to bypass receptor-level resistance, but that introduces confounding variables. Document baseline IGF-1 levels and GH receptor expression if possible. If receptors are already downregulated >70%, sermorelin's efficacy will be limited regardless of dosing optimization.